Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle K Wilson

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncologyAngela Mweempwa, Michelle K Wilson
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in trials of cancer treatment: the past, present, and futureMichelle K Wilson, Katherine Karakasis, Amit M Oza
Cancer|June 17, 2015
Discrepancies in drug approvals: A global dilemmaMichelle K Wilson, Katherine Karakasis, Amit M Oza
Journal of Gynecologic Oncology|July 20, 2018
A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancerMichelle K Wilson, Rebecca Mercieca-Bebber, Michael Friedlander
The Oncologist|November 10, 2017
A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to ImproveMichelle K Wilson, Michael L Friedlander, Florence Joly, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Non-target progression--the fine line between objectivity and subjectivityStephanie Lheureux, Michelle K Wilson, Martin O'Malley, et al.
Cancer|October 4, 2014
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancerVincent Castonguay, Michelle K Wilson, Ivan Diaz-Padilla, et al.
Asia-Pacific Journal of Clinical Oncology|February 28, 2014
Review of high-dose intravenous vitamin C as an anticancer agentMichelle K Wilson, Bruce C Baguley, Clare Wall, et al.
JCO Global Oncology|January 3, 2025
Pacific Peoples' Experiences of Cancer and Its Treatment in Aotearoa New Zealand Through Talanoa: A Qualitative Study of Samoan and Tongan ParticipantsOlivia M Perelini, Vili H Nosa, Michelle K Wilson, et al.
Clinical Epigenetics|July 25, 2017
MicroRNA profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markersWei-Tzu Cheng, Roseanne Rosario, Anita Muthukaruppan, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncologyAngela Mweempwa, Michelle K Wilson
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in trials of cancer treatment: the past, present, and futureMichelle K Wilson, Katherine Karakasis, Amit M Oza
Cancer|June 17, 2015
Discrepancies in drug approvals: A global dilemmaMichelle K Wilson, Katherine Karakasis, Amit M Oza
Journal of Gynecologic Oncology|July 20, 2018
A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancerMichelle K Wilson, Rebecca Mercieca-Bebber, Michael Friedlander
The Oncologist|November 10, 2017
A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to ImproveMichelle K Wilson, Michael L Friedlander, Florence Joly, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Non-target progression--the fine line between objectivity and subjectivityStephanie Lheureux, Michelle K Wilson, Martin O'Malley, et al.
Cancer|October 4, 2014
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancerVincent Castonguay, Michelle K Wilson, Ivan Diaz-Padilla, et al.
Asia-Pacific Journal of Clinical Oncology|February 28, 2014
Review of high-dose intravenous vitamin C as an anticancer agentMichelle K Wilson, Bruce C Baguley, Clare Wall, et al.
JCO Global Oncology|January 3, 2025
Pacific Peoples' Experiences of Cancer and Its Treatment in Aotearoa New Zealand Through Talanoa: A Qualitative Study of Samoan and Tongan ParticipantsOlivia M Perelini, Vili H Nosa, Michelle K Wilson, et al.
Clinical Epigenetics|July 25, 2017
MicroRNA profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markersWei-Tzu Cheng, Roseanne Rosario, Anita Muthukaruppan, et al.
Pageof 2